Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Pertuzumab Biosimilar vs Perjeta in Healthy Men
NCT05825781Phase 1Active, not recruiting
- Sponsor
- Mabscale
- Start
- Jul 2023
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pertuzumab in breast cancer (2 arms), sponsored by Mabscale. Primary endpoint: Concentration of pertuzumab in serum up to 100 days. Started Jul 2023; status: active, not recruiting.
02
Drugs
pertuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05825781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05825781.